Skip to main content
    I

    Immatics NV (IMTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.14
    +0.14 (+2.00%)

    Market Cap: $1.07B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(11/26)
    Avg Surprise
    -9.64%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.50
    Range$-0.54 - $-0.44
    7 analysts
    EPS Revisions
    1
    0
    7d
    3
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.50-1.2%
    60d ago$-0.50-1.3%
    30d ago$-0.50-1.3%
    7d ago$-0.51+1.7%
    Current$-0.50
    Revenue Consensus
    $13M
    Range$7M - $17M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.65
    Range$-0.93 - $-0.49
    7 analysts
    Revenue Consensus
    $11M
    Range$-6856560 - $26M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.65---
    Sep 26EST
    		-$-0.50---
    Jun 26
    Reported Aug 18
    		$-0.53$-0.43-23.26%Miss+22.1%
    Mar 26
    Reported May 12
    		$-0.51$-0.44-15.91%Miss-37.8%
    Dec 25
    Reported Mar 5
    		$-0.34$-0.41+18.05%Beat-174.5%
    Sep 25
    Reported Nov 17
    		$-0.49$-0.45-8.89%Miss-512.5%
    Jun 25
    Reported Aug 13
    		$-0.68$-0.36-88.89%Miss-257.9%
    Mar 25
    Reported May 13
    		$-0.37$-0.33-12.12%Miss-1133.3%
    Dec 24
    Reported Mar 27
    		$0.45$-0.34+234.34%Beat+251.0%
    Sep 24
    Reported Nov 18
    		$-0.08N/A+71.43%Beat+76.5%
    Jun 24
    Reported Aug 13
    		$-0.19$-0.31+38.71%Beat+45.7%
    Mar 24
    Reported May 14
    		$-0.03N/A+86.36%Beat+89.3%
    Dec 23
    Reported Mar 21
    		$-0.30$-0.32+6.25%Beat-30.4%
    Sep 23
    Reported Nov 14
    		$-0.34$-0.39+12.82%Beat-3.0%
    Jun 23
    Reported Aug 17
    		$-0.35$-0.27-29.63%Miss-59.1%
    Mar 23
    Reported May 16
    		$-0.28$-0.30+6.67%Beat-119.3%
    Dec 22
    Reported Mar 21
    		$-0.23$-0.17-35.29%Miss+11.5%
    Sep 22
    Reported Nov 17
    		$-0.33$-0.44+25.00%Beat+32.7%
    Jun 22
    Reported Aug 9
    		$-0.22$-0.06-266.67%Miss+51.1%
    Mar 22
    Reported Jun 2
    		$1.45$1.92-24.48%Miss+453.7%
    Dec 21
    Reported Mar 23
    		$-0.26$0.20-230.00%Miss+44.7%
    Sep 21
    Reported Nov 16
    		$-0.49$-0.34-44.12%Miss-4.3%
    Jun 21
    Reported Aug 10
    		$-0.45$-0.39-15.38%Miss-87.5%
    Mar 21
    Reported May 18
    		$-0.41$-0.40-2.50%Miss-127.8%
    Dec 20
    Reported Mar 30
    		$-0.47N/A+61.48%Beat-2450.0%
    Sep 20
    Reported Dec 2
    		$-0.47$-0.29-62.07%Miss-1666.7%
    Jun 20
    Reported Sep 3
    		$-0.24$-0.16-50.00%Miss-580.0%
    Mar 20
    Reported Jun 8
    		$-0.18N/A+97.48%Beat-550.0%
    Dec 19
    Reported Mar 6
    		$0.02$0.00N/ABeat-
    Sep 19
    Reported Nov 13
    		$0.03$0.00N/ABeat-
    Jun 19
    Reported Aug 12
    		$0.05$0.00N/ABeat-
    Mar 19
    Reported Jun 29
    		$0.04$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.30EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-735.00%
    ROE-47.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage25.09x
    Current Ratio7.54xQuick Ratio7.54x
    Trading Statistics
    Beta1.36Avg Volume949.83K
    52-Week High$12.4152-Week Low$6.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.33
    SMA 20$7.95
    SMA 50$8.72
    SMA 200$9.72
    EMA 10$7.39
    EMA 20$7.81
    EMA 50$8.48
    EMA 200$9.13

    MACD

    Line: -0.50Signal: -0.42Hist: -0.08

    ADX

    ADX: 33.7+DI: 8.9-DI: 31.1

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down96.0
    PSAR$8.33

    Bollinger Bands

    Upper Band$9.32
    Lower Band$6.59
    %B Position3430%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    32.9

    Momentum Oscillators

    Stoch %K9.8
    Stoch %D8.9
    Williams %R-83.1
    ROC (10d)-15.4%
    Momentum-1.30
    CCI (20d)-95.0
    MFI (14d)56.8

    Volatility Measures

    ATR (14d)$0.42(5.9%)
    StdDev (20d)0.68
    Hist Vol51.0%(High)

    Volume Flow

    VWAP$7.10
    OBV17.1M
    AD Line2.0M
    CMF (20d)-0.021

    Volume Metrics

    Avg Vol (20d)987.8K
    Vol Ratio1.5x
    VWMA (20d)$7.89

    Pivot Points

    R3$7.69
    R2$7.45
    R1$7.22
    Pivot Point$6.98
    S1$6.75
    S2$6.51
    S3$6.28

    Advanced Oscillators

    TSI-36.48
    Ultimate Osc44.5
    KST-165.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.14M$7.61M$19.76M$5.19M$4.74M$18.58M$56.25M$50.56M$18.75M$30.27M$15.92M$5.93M
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/A$38.91M$94,860$32.11M$33.27M$30.50M
    Gross Profit$9.14M$7.61M$19.76M$5.19M$4.74M$18.58M$56.25M$50.56M$18.75M$30.27M$15.92M$-24,572,000
    Operating Expenses$76.35M$73.68M$58.64M$59.82M$57.86M$53.96M$55.35M$50.05M$45.32M$43.74M$43.63M$8.70M
    R&D$62.41M$59.19M$49.64M$47.18M$45.11M$41.91M$41.85M$38.91M$35.22M$32.11M$33.27M$30.50M
    SG&A$13.94M$14.51M$13.66M$12.67M$12.78M$12.07M$13.52M$11.16M$10.13M$11.64M$10.37M$8.88M
    Operating Income$-67,204,000$-66,064,000$-38,881,000$-54,633,000$-53,127,000$-35,374,000$903,000$514,000$-26,564,000$-13,469,000$-27,714,000$-33,267,000
    Interest Income$3.29M$3.58M$3.55M$3.91M$4.26M$5.46M$6.82M$5.53M$6.37M$6.29M$4.85M$3.99M
    Interest Expense$203,000$212,000$222,000$231,000$244,000$249,000$232,000$235,000$226,000$194,000$211,000$218,000
    Income Before Tax$-62,766,000$-57,762,000$-35,564,000$-50,672,000$-71,349,000$-40,849,000$43.27M$-2,353,000$-17,852,000$-1,722,000$-26,148,000$-26,489,000
    Income Tax Expense$-274,000$52,000$134,000$-127,000$-1,001,000$-994,000$-1,592,000$6.22M$140,000$518,000$211,000$218,000
    Net Income$-62,492,000$-57,814,000$-35,698,000$-50,545,000$-70,348,000$-39,855,000$44.86M$-8,570,000$-17,992,000$-2,240,000$-26,148,000$-26,489,000
    EBITDA$-59,511,297$-54,775,000$-32,173,000$-47,376,000$-68,079,000$-37,460,000$46.58M$915,000$-14,524,000$1.49M$-24,135,000$-31,501,000
    EBIT$-62,563,000$-57,550,000$-35,342,000$-50,441,000$-71,105,000$-40,600,000$43.50M$-2,118,000$-17,626,000$-1,528,000$-25,937,000$-33,267,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMTX

    News

    Stifel initiated Buy coverage of Immatics stock at USD 15 target

    Stifel initiated Buy coverage of Immatics stock (IMTX) with a USD 15 price target on October 13, 2026. This target represents a significant premium over Immatics' current trading price and Nasdaq close...

    ad-hoc-news.de•10/15/26•Bullish

    Stifel initiates Immatics stock with buy rating on melanoma potential By Investing.com

    Stifel initiated coverage on Immatics N.V. (NASDAQ:IMTX) with a buy rating and a $15.00 price target, highlighting the company's dual-modality approach to targeting melanoma. The analyst noted that Immatics is...

    Investing.com India•10/14/26•Bullish

    IMTX Initiates Coverage On Stifel -- Rating Set to Buy with $15 Price Target

    Stifel has initiated coverage on Immatics (IMTX) with a Buy rating and a $15 price target, signaling optimism for the biopharmaceutical company focused on T-cell immunotherapies. Despite this positive analyst outlook...

    GuruFocus•10/14/26•Neutral

    Stifel initiates Immatics stock with buy rating on melanoma potential

    Stifel initiated coverage on Immatics N.V. (NASDAQ:IMTX) with a buy rating and a $15.00 price target, citing the company's dual-modality approach to targeting melanoma. The firm projects global sales of approximately...

    Investing.com•10/13/26•Bullish

    Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to Brokerages

    Immatics N.V. (NASDAQ:IMTX) has received a "Moderate Buy" consensus rating from eight research firms, with an average 12-month price target of $20.60...

    MarketBeat•10/10/26•Somewhat-Bearish

    IMTX Valuation and Fair Value

    P/E
    -3.3x
    P/B
    2.1x
    See GNG's fair value

    IMTX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -735.0%
    Net margin
    0.0%
    ROE
    -47.8%
    FCF margin
    -430.8%

    IMTX Competitors

    CompanyTicker
    Replimune Group IncREPL
    Enovis CorpENOV
    Procept Biorobotics CorpPRCT
    Janux Therapeutics IncJANX
    Teladoc IncTDOC
    CureVac NVCVAC
    STAAR Surgical CompanySTAA
    Artivion IncAORT

    Sector: Healthcare

    IMTX Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IMTX Bull Case vs Bear Case

    Bull case

    • IMTX grew quarterly revenue 93.0% year over year.
    • 100.0% of IMTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • IMTX beat EPS estimates in 37.5% of its last 8 reported quarters.

    IMTX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    21.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.50
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 4 down

    Frequently Asked Questions About IMTX

    Does IMTX pay dividends?

    Immatics NV (IMTX) does not currently pay a regular dividend.

    What is IMTX's market cap?

    Immatics NV (IMTX) has a market capitalization of $1.07B with a current stock price of $7.14.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In